TrialBreast cancer research : BCR2025

Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.

Roberto A Leon-Ferre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.